AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29953626 — intervention group
Group type: EXPERIMENTAL
Intervention: Community HUGS (CHUGS) intervention
Number of subjects: 74
Study 29953626 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 74
Study 27306315 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy (CBTuhr)
Number of subjects: 196
Study 27306315 — intervention group
Group type: COMPARATOR
Intervention: Routine Care (RC)
Number of subjects: 196
Study 26268565 — intervention group
Group type: EXPERIMENTAL
Intervention: Omegaven (omega-3 fatty acids)
Number of subjects: 258
Study 26268565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 258
Study 22377324 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5g HA‐CMC
Number of subjects: 27
Study 22377324 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 27
Study 21486265 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive parenting behaviors toward 14-month-old children
Number of subjects: 1240
Study 21486265 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive parenting, higher family resources, lower family conflict
Number of subjects: 1240
Study 21486265 — intervention group
Group type: EXPERIMENTAL
Intervention: Supportive parenting, support for language and learning in the home environment, higher family resources
Number of subjects: 1240
Study 21486265 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal age
Number of subjects: 1240
Study 19646783 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotecno gowns
Number of subjects: 56
Study 19646783 — intervention group
Group type: COMPARATOR
Intervention: Gore gowns
Number of subjects: 56
Study 17766507 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived milk intolerance
Number of subjects: 291
Study 17766507 — intervention group
Group type: COMPARATOR
Intervention: Lactose maldigestion
Number of subjects: 291
Study 15153167 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine continued treatment
Number of subjects: 29
Study 15153167 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine withdrawal
Number of subjects: 29
Study 15153167 — intervention group
Group type: EXPERIMENTAL
Intervention: Azathioprine continued treatment (dose >1.60 mg/kg/day)
Number of subjects: 29
Study 15153167 — intervention group
Group type: COMPARATOR
Intervention: Azathioprine withdrawal (dose >1.60 mg/kg/day)
Number of subjects: 29
Study 11485124 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulfasalazine 500 mg tablets twice daily
Number of subjects: 31
Study 11485124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study 9589379 — intervention group
Group type: EXPERIMENTAL
Intervention: DM-CRF (patients with diabetes mellitus and chronic renal failure)
Number of subjects: 40
Study 9589379 — intervention group
Group type: COMPARATOR
Intervention: non-DM-CRF (patients with renal failure due to other causes)
Number of subjects: 40
Study 9589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of diabetes mellitus (DM)
Number of subjects: 40
Study 9589379 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher serum creatinine levels
Number of subjects: 40
Study 7602728 — intervention group
Group type: EXPERIMENTAL
Intervention: Auscultation (progression of loudest sound locations from left to right abdomen)
Number of subjects: 106
Study 7602728 — intervention group
Group type: EXPERIMENTAL
Intervention: Vacuum effect (change from 40 mL of aspirated air to ≤ 10 mL after 60 mL of air instillation)
Number of subjects: 106
Study 7602728 — intervention group
Group type: EXPERIMENTAL
Intervention: pH change (from ≤ 4.0 to ≥ 6.0)
Number of subjects: 106
Study 7602728 — intervention group
Group type: EXPERIMENTAL
Intervention: Color change (to yellow)
Number of subjects: 106
Study 3245698 — intervention group
Group type: EXPERIMENTAL
Intervention: Miconazole
Number of subjects: 0
Study 3245698 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B (AmB)
Number of subjects: 0
Study 29191136 — intervention group
Group type: EXPERIMENTAL
Intervention: Collaborative care
Number of subjects: 35
Study 29191136 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 35
Study 26714972 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium levels <3.5 mEq/L
Number of subjects: 6515
Study 26714972 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium levels ⩾5 mEq/L
Number of subjects: 6515
Study 26714972 — intervention group
Group type: COMPARATOR
Intervention: Potassium levels 3.5 to <4 mEq/L
Number of subjects: 6515
Study 26714972 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium levels ⩾4.5 mEq/L
Number of subjects: 6515
Study 26623654 — intervention group
Group type: EXPERIMENTAL
Intervention: Group-based structured education workshop focused on sitting reduction, self-monitoring tool, and follow-up motivational phone call
Number of subjects: 187
Study 26623654 — intervention group
Group type: COMPARATOR
Intervention: Control group (details not specified)
Number of subjects: 187
Study 23229850 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholestyramine ointment (15%)
Number of subjects: 91
Study 23229850 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 91
Study 21287417 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional counseling program
Number of subjects: 53
Study 21287417 — intervention group
Group type: COMPARATOR
Intervention: Control group (no nutritional counseling)
Number of subjects: 53
Study 18952497 — intervention group
Group type: EXPERIMENTAL
Intervention: Pramipexole (flexibly titrated from 0.25 to 0.75mg, 2‐3h before bedtime for 12 weeks)
Number of subjects: 357
Study 18952497 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 357
Study 16645371 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Nitric Oxide (iNO)
Number of subjects: 58
Study 16645371 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled Prostacyclin (iPGI2)
Number of subjects: 58
Study 16645371 — intervention group
Group type: COMPARATOR
Intervention: Intravenous vasodilators (Control)
Number of subjects: 58
Study 16645371 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled drugs (iNO and iPGI2)
Number of subjects: 58
Study 12540121 — intervention group
Group type: EXPERIMENTAL
Intervention: Er:YAG laser irradiation
Number of subjects: 67
Study 12540121 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAP laser irradiation
Number of subjects: 67
Study 12540121 — intervention group
Group type: EXPERIMENTAL
Intervention: Acid-etch treatment
Number of subjects: 67
Study 10971787 — intervention group
Group type: EXPERIMENTAL
Intervention: French-press coffee
Number of subjects: 46
Study 8781869 — intervention group
Group type: COMPARATOR
Intervention: Caffeine 0 mg.kg‐1 body mass
Number of subjects: 7
Study 8781869 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 5 mg.kg‐1 body mass
Number of subjects: 7
Study 8781869 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine 9 mg.kg‐1 body mass
Number of subjects: 7
Study 8781869 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (all doses)
Number of subjects: 7
Study 1727841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,000 mg/day, 1,250 mg/day, 1,500 mg/day, or 2,000 mg/day for 8 weeks
Number of subjects: 158
Study 1727841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin) at doses of 1,500 mg and 2,000 mg for older subjects
Number of subjects: 158
Study 1727841 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotinic acid (wax-matrix sustained-release niacin, Endur-acin)
Number of subjects: 158
Study 6086834 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive community treatment including a 24-hour crisis service
Number of subjects: 120
Study 6086834 — intervention group
Group type: COMPARATOR
Intervention: Standard psychiatric hospital care and aftercare
Number of subjects: 120
Study 6086834 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive community treatment
Number of subjects: 120
Study 31241003 — intervention group
Group type: EXPERIMENTAL
Intervention: VA (virus agency) messages
Number of subjects: 216
Study 31241003 — intervention group
Group type: EXPERIMENTAL
Intervention: PF (positive framing) messages
Number of subjects: 216
Study 31241003 — intervention group
Group type: EXPERIMENTAL
Intervention: VA*PF (virus agency and positive framing)
Number of subjects: 216
Study 31241003 — intervention group
Group type: COMPARATOR
Intervention: HA (human agency) and NF (negative framing) messages
Number of subjects: 216
Study 29257795 — intervention group
Group type: EXPERIMENTAL
Intervention: Halftime rewarm-up (RW) with intermittent exercise for 15 minutes
Number of subjects: 10
Study 29257795 — intervention group
Group type: COMPARATOR
Intervention: Control (resting on a chair during halftime)
Number of subjects: 10
Study 29257795 — intervention group
Group type: EXPERIMENTAL
Intervention: Halftime rewarm-up (RW) with intermittent exercise
Number of subjects: 10
Study 26584896 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain Recognition and Treatment (PRT) protocol coupled with basic pain education
Number of subjects: 195
Study 26584896 — intervention group
Group type: COMPARATOR
Intervention: Basic pain education alone
Number of subjects: 195
Study 24571483 — intervention group
Group type: EXPERIMENTAL
Intervention: Azilsartan
Number of subjects: 17
Study 22424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Super short pulse (SSP) Er:YAG laser
Number of subjects: 60
Study 22424269 — intervention group
Group type: COMPARATOR
Intervention: Steel bur (SB)
Number of subjects: 60
Study 22424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium short pulse (MSP) Er:YAG laser
Number of subjects: 60
Study 22424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Short pulse (SP) Er:YAG laser
Number of subjects: 60
Study 22424269 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluorescence feedback-controlled (FFC) Er:YAG laser
Number of subjects: 60
Study 19761871 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg b.i.d.)
Number of subjects: 173
Study 19761871 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E (400 IU b.i.d.)
Number of subjects: 173
Study 19761871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 173
Study 19761871 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin or Vitamin E
Number of subjects: 173
Study 17043050 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-mediated individualized intervention (52 weeks)
Number of subjects: 82
Study 17043050 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 82
Study 15505091 — intervention group
Group type: EXPERIMENTAL
Intervention: Additional ablation lines along the left atrial septum, roof, and/or anterior wall where there were fractionated electrograms (group 3; 30 patients)
Number of subjects: 100
Study 15505091 — intervention group
Group type: COMPARATOR
Intervention: No further ablation (group 2; 30 patients)
Number of subjects: 100
Study 15505091 — intervention group
Group type: EXPERIMENTAL
Intervention: Left atrial flutter
Number of subjects: 100
Study 11273580 — intervention group
Group type: EXPERIMENTAL
Intervention: Valid colour cues in a high-load condition
Number of subjects: 0
Study 11273580 — intervention group
Group type: EXPERIMENTAL
Intervention: Colour cues in a low-load condition
Number of subjects: 0
Study 11273580 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of target colour
Number of subjects: 0
Study 9805215 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-fat ice cream (3% fat)
Number of subjects: 16
Study 9805215 — intervention group
Group type: COMPARATOR
Intervention: Standard ice cream (10% fat)
Number of subjects: 16
Study 7999483 — intervention group
Group type: EXPERIMENTAL
Intervention: Active smokers
Number of subjects: 0
Study 7999483 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive smokers
Number of subjects: 0
Study 7999483 — intervention group
Group type: COMPARATOR
Intervention: Non-smokers
Number of subjects: 0
Study 7999483 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (regardless of smoking status)
Number of subjects: 0
Study 7999483 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking status
Number of subjects: 0
Study 3056240 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin (total dose, 2.4 g) plus Amikacin (total dose, 1 g)
Number of subjects: 113
Study 3056240 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin plus Clavulanic acid (total dose, 20.8 g)
Number of subjects: 113
Study 3056240 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus Amikacin
Number of subjects: 113
Study 3056240 — intervention group
Group type: COMPARATOR
Intervention: Ticarcillin plus Clavulanic acid
Number of subjects: 113
Study 31104113 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich fibrin (PRF)
Number of subjects: 40
Study 31104113 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 40
Study 30658678 — intervention group
Group type: EXPERIMENTAL
Intervention: Seattle-PAP
Number of subjects: 230
Study 30658678 — intervention group
Group type: COMPARATOR
Intervention: FP-CPAP (Fisher & Paykel CPAP)
Number of subjects: 230
Study 28911260 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod 0.1 mg, 0.2 mg, or 0.4 mg
Number of subjects: 367
Study 28911260 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod (various doses)
Number of subjects: 367
Study 28911260 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiselimod
Number of subjects: 367
Study 27497361 — intervention group
Group type: EXPERIMENTAL
Intervention: Svelte sirolimus‐eluting coronary stent‐on‐a‐wire Integrated Delivery System (IDS)
Number of subjects: 159
Study 27497361 — intervention group
Group type: COMPARATOR
Intervention: Resolute Integrity zotarolimus‐eluting stent with durable polymer
Number of subjects: 159
Study 24478047 — intervention group
Group type: EXPERIMENTAL
Intervention: Taking Care of Sugar DSME program
Number of subjects: 25
Study 22846379 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking exercise program (6-month home-based)
Number of subjects: 20
Study 22846379 — intervention group
Group type: COMPARATOR
Intervention: Standard medical advice (Control Group)
Number of subjects: 20
Study 20621419 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone
Number of subjects: 40
Study 20621419 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 20621419 — intervention group
Group type: EXPERIMENTAL
Intervention: Static QST (heat pain thresholds)
Number of subjects: 40
Study 20621419 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic QST (temporal summation)
Number of subjects: 40
Study 17717914 — intervention group
Group type: EXPERIMENTAL
Intervention: Strengthening Pi and activating blood circulation therapy (SPAB)
Number of subjects: 70
Study 17717914 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin and methopterin (Western medicine)
Number of subjects: 70
Study 17717914 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of SPAB and Western medicine (CM-WM group)
Number of subjects: 70
Study 15828855 — intervention group
Group type: EXPERIMENTAL
Intervention: NuvaRing alone for 21 days
Number of subjects: 0
Study 15828855 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing for 21 days plus amoxicillin on days 1‐10
Number of subjects: 0
Study 15828855 — intervention group
Group type: COMPARATOR
Intervention: NuvaRing for 21 days plus doxycycline
Number of subjects: 0
Study 12097784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day reinitiated after relapse from placebo
Number of subjects: 122
Study 12097784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg/day (increased from 20 mg/day)
Number of subjects: 122
Study 12097784 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 90 mg twice a week (increased from 90 mg weekly)
Number of subjects: 122
Study 12097784 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 11057105 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced bacteriologically confirmed pulmonary tuberculosis (I group)
Number of subjects: 2
Study 11057105 — intervention group
Group type: COMPARATOR
Intervention: Minimal TB changes, usually without clinical signs of the disease, and sputum smear-negative (II group)
Number of subjects: 2
Study 11057105 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined in the abstract)
Number of subjects: 2
Study 8851780 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifting belt
Number of subjects: 16
Study 8851780 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot motion
Number of subjects: 16
Study 8851780 — intervention group
Group type: COMPARATOR
Intervention: Control (no lifting belt)
Number of subjects: 16
Study 1979763 — intervention group
Group type: EXPERIMENTAL
Intervention: Highly purified pork insulin (Actrapid)
Number of subjects: 8
Study 1979763 — intervention group
Group type: EXPERIMENTAL
Intervention: Semisynthetic human insulin (Actrapid Human)
Number of subjects: 8
Study 34496 — intervention group
Group type: EXPERIMENTAL
Intervention: Triazolam (0.6 mg)
Number of subjects: 0
Study 34496 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurazepam (30 mg)
Number of subjects: 0
Study 31842189 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-VEGF therapy
Number of subjects: 185
Study 31470091 — intervention group
Group type: EXPERIMENTAL
Intervention: Stereotactic Ablative Radiation Therapy (SABR)
Number of subjects: 99
Study 31470091 — intervention group
Group type: COMPARATOR
Intervention: Standard of Care (SOC)
Number of subjects: 99
Study 26152493 — intervention group
Group type: EXPERIMENTAL
Intervention: Simple task group
Number of subjects: 28
Study 26152493 — intervention group
Group type: COMPARATOR
Intervention: Complex task group
Number of subjects: 28
Study 24434301 — intervention group
Group type: EXPERIMENTAL
Intervention: Low doses of atorvastatin (10 mg daily) or simvastatin (10-20 mg daily)
Number of subjects: 115
Study 24434301 — intervention group
Group type: COMPARATOR
Intervention: Statin-free patients with type 2 diabetes
Number of subjects: 115
Study 24434301 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic subjects
Number of subjects: 115
Study 21890323 — intervention group
Group type: EXPERIMENTAL
Intervention: pONS (carbohydrate-containing preconditioning oral nutritional supplement enriched with glutamine, antioxidants, and green tea extract)
Number of subjects: 36
Study 21890323 — intervention group
Group type: EXPERIMENTAL
Intervention: pONS
Number of subjects: 36
Study 21890323 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 36
Study 19598302 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic combination of Lactobacillus acidophilus NCFM and Bifidobacterium lactis Bl‐04
Number of subjects: 47
Study 19598302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 17599487 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel discontinued more than 6 days before surgery (group 1, n = 35)
Number of subjects: 106
Study 17599487 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel continued until 3 to 5 days before surgery (group 2, n = 51)
Number of subjects: 106
Study 17599487 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin and clopidogrel continued within 2 days of surgery (group 3, n = 20)
Number of subjects: 106
Study 15141801 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 0.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Number of subjects: 34
Study 15141801 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Number of subjects: 34
Study 15141801 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil 1.5 microg kg(‐1) i.v. with propofol 2 mg kg(‐1) i.v. and 60% nitrous oxide in oxygen
Number of subjects: 34
Study 11841525 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention arm of a trial of the effectiveness of depression treatment
Number of subjects: 239
Study 11841525 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-centered barriers
Number of subjects: 239
Study 11841525 — intervention group
Group type: EXPERIMENTAL
Intervention: Physician-centered barriers
Number of subjects: 239
Study 11841525 — intervention group
Group type: EXPERIMENTAL
Intervention: System barriers
Number of subjects: 239
Study 11841525 — intervention group
Group type: EXPERIMENTAL
Intervention: Cluster analysis of barrier scores
Number of subjects: 239
Study 9823729 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% KTP gel
Number of subjects: 42
Study 9823729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% KTP gel
Number of subjects: 42
Study 9823729 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% KTP alternate gel
Number of subjects: 42
Study 9823729 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.0% KTP gel
Number of subjects: 42
Study 9823729 — intervention group
Group type: COMPARATOR
Intervention: 25 mg KTP capsule (positive control)
Number of subjects: 42
Study 9823729 — intervention group
Group type: EXPERIMENTAL
Intervention: All gel formulations
Number of subjects: 42
Study 9823729 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments
Number of subjects: 42
Study 7714603 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 mg/kg tirilazad per day intravenously
Number of subjects: 245
Study 7714603 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg/kg tirilazad per day intravenously
Number of subjects: 245
Study 7714603 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 mg/kg tirilazad per day intravenously
Number of subjects: 245
Study 7714603 — intervention group
Group type: COMPARATOR
Intervention: Vehicle (control)
Number of subjects: 245
Study 2468745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone (14 mg/m2 IV every 3 weeks)
Number of subjects: 325
Study 2468745 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin (75 mg/m2 IV every 3 weeks)
Number of subjects: 325
Study 2468745 — intervention group
Group type: EXPERIMENTAL
Intervention: Mitoxantrone
Number of subjects: 325
Study 2468745 — intervention group
Group type: COMPARATOR
Intervention: Doxorubicin
Number of subjects: 325
Study 86292 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional personalized counseling for 3 months
Number of subjects: 211
Study 86292 — intervention group
Group type: EXPERIMENTAL
Intervention: Matched instruction (Group IIa)
Number of subjects: 211